JP2022524337A5 - - Google Patents
Info
- Publication number
- JP2022524337A5 JP2022524337A5 JP2021552717A JP2021552717A JP2022524337A5 JP 2022524337 A5 JP2022524337 A5 JP 2022524337A5 JP 2021552717 A JP2021552717 A JP 2021552717A JP 2021552717 A JP2021552717 A JP 2021552717A JP 2022524337 A5 JP2022524337 A5 JP 2022524337A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962814210P | 2019-03-05 | 2019-03-05 | |
| US201962814159P | 2019-03-05 | 2019-03-05 | |
| US62/814,159 | 2019-03-05 | ||
| US62/814,210 | 2019-03-05 | ||
| US201962814744P | 2019-03-06 | 2019-03-06 | |
| US62/814,744 | 2019-03-06 | ||
| US201962826523P | 2019-03-29 | 2019-03-29 | |
| US62/826,523 | 2019-03-29 | ||
| PCT/US2020/021276 WO2020181145A1 (en) | 2019-03-05 | 2020-03-05 | Conditionally activated binding proteins containing fc regions and moieties targeting tumor antigens |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022524337A JP2022524337A (ja) | 2022-05-02 |
| JPWO2020181145A5 JPWO2020181145A5 (https=) | 2023-03-13 |
| JP2022524337A5 true JP2022524337A5 (https=) | 2023-03-13 |
Family
ID=70058513
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021552717A Ceased JP2022524337A (ja) | 2019-03-05 | 2020-03-05 | 腫瘍抗原を標的とするｆｃ領域及び部分を含有する条件的に活性化された結合タンパク質 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20220144949A1 (https=) |
| EP (1) | EP3934761A1 (https=) |
| JP (1) | JP2022524337A (https=) |
| CN (1) | CN114173876A (https=) |
| AU (1) | AU2020231391A1 (https=) |
| CA (1) | CA3132651A1 (https=) |
| WO (1) | WO2020181145A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA201792573A1 (ru) | 2015-05-21 | 2018-04-30 | Харпун Терапьютикс, Инк. | Триспецифические связанные белки и способы их применения |
| US12128102B2 (en) | 2016-03-08 | 2024-10-29 | Takeda Pharmaceutical Company Limited | Constrained conditionally activated binding proteins |
| JP7101621B2 (ja) | 2016-05-20 | 2022-07-15 | ハープーン セラピューティクス，インク． | 単一ドメイン血清アルブミン結合タンパク質 |
| IL302613B2 (en) | 2017-09-08 | 2025-04-01 | Maverick Therapeutics Inc | Binding proteins are activated under limited conditions |
| IL315737A (en) | 2017-10-13 | 2024-11-01 | Harpoon Therapeutics Inc | B-cell maturation antigen-binding proteins |
| HRP20241268T1 (hr) | 2017-10-13 | 2024-12-06 | Harpoon Therapeutics, Inc. | Trispecifični proteini i postupci primjene |
| WO2020061482A1 (en) | 2018-09-21 | 2020-03-26 | Harpoon Therapeutics, Inc. | Egfr binding proteins and methods of use |
| SG11202103022WA (en) | 2018-09-25 | 2021-04-29 | Harpoon Therapeutics Inc | Dll3 binding proteins and methods of use |
| WO2020181140A1 (en) | 2019-03-05 | 2020-09-10 | Maverick Therapeutics, Inc. | Constrained conditionally activated binding proteins |
| AU2021396172A1 (en) | 2020-12-09 | 2023-07-06 | Janux Therapeutics, Inc. | Compositions and methods related to tumor activated antibodies targeting psma and effector cell antigens |
| WO2023064945A2 (en) * | 2021-10-15 | 2023-04-20 | Harpoon Therapeutics, Inc. | Conditional activation of immunoglobulin molecules |
| WO2026038050A2 (en) * | 2024-08-14 | 2026-02-19 | Creasallis Ltd | Agents, methods and uses thereof |
| WO2026038047A2 (en) * | 2024-08-14 | 2026-02-19 | Creasallis Ltd | Agents, methods and uses thereof |
| WO2026038048A2 (en) * | 2024-08-14 | 2026-02-19 | Creasallis Ltd | Agents, methods and uses thereof |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| JP3534749B2 (ja) | 1991-08-20 | 2004-06-07 | アメリカ合衆国 | アデノウイルスが介在する胃腸管への遺伝子の輸送 |
| WO1993006217A1 (en) | 1991-09-19 | 1993-04-01 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES |
| US5252479A (en) | 1991-11-08 | 1993-10-12 | Research Corporation Technologies, Inc. | Safe vector for gene therapy |
| FR2688514A1 (fr) | 1992-03-16 | 1993-09-17 | Centre Nat Rech Scient | Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant. |
| AU680459B2 (en) | 1992-12-03 | 1997-07-31 | Genzyme Corporation | Gene therapy for cystic fibrosis |
| ES2249761T3 (es) | 1993-06-24 | 2006-04-01 | Advec Inc. | Vectores de adenovirus para terapia genica. |
| EP1637608B1 (en) | 1993-10-25 | 2009-07-22 | CANJI, Inc. | Recombinant adenoviral vector and methods of use |
| US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
| US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
| CN100427603C (zh) | 1999-10-04 | 2008-10-22 | 麦迪卡格公司 | 调控外源基因转录的方法 |
| US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
| DE10231109A1 (de) | 2002-07-10 | 2004-01-22 | Daimlerchrysler Ag | Abgasturbine |
| AU2015323313B2 (en) * | 2014-09-25 | 2021-04-01 | Amgen Inc. | Protease-activatable bispecific proteins |
| ES2873846T5 (en) * | 2015-11-19 | 2025-06-23 | Revitope Ltd | Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells |
| KR20230041739A (ko) * | 2016-03-08 | 2023-03-24 | 매버릭 테라퓨틱스, 인크. | 유도성 결합 단백질 및 사용 방법 |
| EP3589662A4 (en) * | 2017-02-28 | 2020-12-30 | Harpoon Therapeutics, Inc. | INDUCTIBLE MONOVALENT ANTIGEN BINDING PROTEIN |
| IL302613B2 (en) * | 2017-09-08 | 2025-04-01 | Maverick Therapeutics Inc | Binding proteins are activated under limited conditions |
| WO2019051122A2 (en) | 2017-09-08 | 2019-03-14 | Maverick Therapeutics, Inc. | CONDITIONAL ACTIVATED BOND FRACTIONS CONTAINING FC REGIONS |
| KR20210020903A (ko) * | 2018-05-14 | 2021-02-24 | 하푼 테라퓨틱스, 인크. | 면역글로불린 분자의 조건부 활성화를 위한 결합 모이어티 |
| WO2020033837A1 (en) * | 2018-08-09 | 2020-02-13 | Maverick Therapeutics, Inc. | Coexpression and purification method of conditionally activated binding proteins |
-
2020
- 2020-03-05 US US17/435,931 patent/US20220144949A1/en not_active Abandoned
- 2020-03-05 EP EP20716051.6A patent/EP3934761A1/en not_active Withdrawn
- 2020-03-05 JP JP2021552717A patent/JP2022524337A/ja not_active Ceased
- 2020-03-05 CN CN202080033827.6A patent/CN114173876A/zh active Pending
- 2020-03-05 WO PCT/US2020/021276 patent/WO2020181145A1/en not_active Ceased
- 2020-03-05 CA CA3132651A patent/CA3132651A1/en active Pending
- 2020-03-05 AU AU2020231391A patent/AU2020231391A1/en not_active Abandoned